[go: up one dir, main page]

EP2432771A4 - Isoxazolines as inhibitors of fatty acid amide hydrolase - Google Patents

Isoxazolines as inhibitors of fatty acid amide hydrolase

Info

Publication number
EP2432771A4
EP2432771A4 EP10778279.9A EP10778279A EP2432771A4 EP 2432771 A4 EP2432771 A4 EP 2432771A4 EP 10778279 A EP10778279 A EP 10778279A EP 2432771 A4 EP2432771 A4 EP 2432771A4
Authority
EP
European Patent Office
Prior art keywords
isoxazolines
inhibitors
fatty acid
acid amide
amide hydrolase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10778279.9A
Other languages
German (de)
French (fr)
Other versions
EP2432771A1 (en
Inventor
Mark L Behnke
Alfredo C Castro
Lawrence K Chan
Catherine A Evans
Louis Grenier
Michael J Grogan
Yves Leblanc
Tao Liu
Stephane Peluso
Daniel A Snyder
Thomas T Tibbitts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Infinity Pharmaceuticals Inc
Original Assignee
Infinity Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Infinity Pharmaceuticals Inc filed Critical Infinity Pharmaceuticals Inc
Publication of EP2432771A1 publication Critical patent/EP2432771A1/en
Publication of EP2432771A4 publication Critical patent/EP2432771A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
EP10778279.9A 2009-05-18 2010-05-18 Isoxazolines as inhibitors of fatty acid amide hydrolase Withdrawn EP2432771A4 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US17928009P 2009-05-18 2009-05-18
US17928509P 2009-05-18 2009-05-18
US17928309P 2009-05-18 2009-05-18
PCT/US2010/035309 WO2010135360A1 (en) 2009-05-18 2010-05-18 Isoxazolines as inhibitors of fatty acid amide hydrolase

Publications (2)

Publication Number Publication Date
EP2432771A1 EP2432771A1 (en) 2012-03-28
EP2432771A4 true EP2432771A4 (en) 2013-06-05

Family

ID=43126477

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10778279.9A Withdrawn EP2432771A4 (en) 2009-05-18 2010-05-18 Isoxazolines as inhibitors of fatty acid amide hydrolase

Country Status (16)

Country Link
EP (1) EP2432771A4 (en)
JP (1) JP2012527467A (en)
KR (1) KR20120042766A (en)
CN (1) CN102459202B (en)
AR (1) AR076687A1 (en)
AU (1) AU2010249674A1 (en)
BR (1) BRPI1011049A2 (en)
CA (1) CA2762527A1 (en)
IL (1) IL216420A0 (en)
MX (1) MX2011012263A (en)
NZ (2) NZ619076A (en)
RU (1) RU2539595C2 (en)
SG (2) SG10201402443PA (en)
TW (1) TW201043620A (en)
WO (1) WO2010135360A1 (en)
ZA (1) ZA201108657B (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10954231B2 (en) 2006-10-16 2021-03-23 Bionomics Limited Anxiolytic compounds
PL2074123T3 (en) 2006-10-16 2013-04-30 Bionomics Ltd Novel anxiolytic compounds
US8927551B2 (en) 2009-05-18 2015-01-06 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
US9149465B2 (en) 2009-05-18 2015-10-06 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
US20130150346A1 (en) 2010-01-08 2013-06-13 Quest Ventures Ltd. Use of FAAH Inhibitors for Treating Parkinson's Disease and Restless Legs Syndrome
WO2011123719A2 (en) 2010-03-31 2011-10-06 Ironwood Pharmaceuticals, Inc. Use of faah inhibitors for treating abdominal, visceral and pelvic pain
AU2012222874B2 (en) 2011-03-02 2015-04-16 Bionomics Limited Novel small-molecules as therapeutics
CA2835450C (en) 2011-05-12 2020-05-12 Bionomics Limited Methods for preparing naphthyridines
WO2018112843A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
CA3072420A1 (en) * 2017-08-10 2019-02-14 Taisho Pharmaceutical Co., Ltd. Pyridine compound substituted with azole
US10485790B1 (en) 2018-09-13 2019-11-26 Syneurx International (Taiwan) Corp. Salts of cycloserine compounds and applications thereof
EP3866798A4 (en) * 2018-10-15 2022-07-13 Dana-Farber Cancer Institute, Inc. Transcriptional enhanced associate domain (tead) transcription factor inhibitors and uses thereof
CN110016142B (en) * 2019-04-30 2021-08-03 合肥工业大学 A kind of silicone oil containing pyrimidine boronic acid structure and preparation method thereof
SG11202113129UA (en) 2019-05-31 2021-12-30 Ikena Oncology Inc Tead inhibitors and uses thereof
CA3141826A1 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
MX2023009402A (en) 2021-02-11 2023-08-23 Basf Se Substituted isoxazoline derivatives.
EP4043444A1 (en) 2021-02-11 2022-08-17 Basf Se Substituted isoxazoline derivatives
CN116888101A (en) * 2021-02-11 2023-10-13 巴斯夫欧洲公司 Substituted isoxazoline derivatives
US20250051338A1 (en) 2021-10-25 2025-02-13 Kymera Therapeutics, Inc. Tyk2 degraders and uses thereof
EP4238971A1 (en) 2022-03-02 2023-09-06 Basf Se Substituted isoxazoline derivatives
EP4486740A1 (en) 2022-03-02 2025-01-08 Basf Se Substituted isoxazoline derivatives
EP4342885A1 (en) 2022-09-20 2024-03-27 Basf Se N-(3-(aminomethyl)-phenyl)-5-(4-phenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-amine derivatives and similar compounds as pesticides
CN120152959A (en) 2022-09-20 2025-06-13 巴斯夫欧洲公司 N-(3-(Aminomethyl)-phenyl)-5-(4-phenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-amine derivatives and similar compounds as pesticides

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1813606A1 (en) * 2004-11-18 2007-08-01 Takeda Pharmaceutical Company Limited Amide compound
WO2009094445A2 (en) * 2008-01-25 2009-07-30 E. I. Du Pont De Nemours And Company Fungicidal hetercyclic compounds

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9505651D0 (en) * 1995-03-21 1995-05-10 Agrevo Uk Ltd AgrEvo UK Limited
US7662971B2 (en) * 2002-10-08 2010-02-16 The Scripps Research Institute Inhibitors of fatty acid amide hydrolase
CA2506026A1 (en) * 2002-11-14 2004-05-27 The Scripps Research Institute Crystalline form of fatty acid amine hydrolase (faah)
WO2005034952A2 (en) * 2003-10-07 2005-04-21 The Feinstein Institute For Medical Research Isoxazole and isothiazole compounds useful in the treatment of inflammation
FR2866888B1 (en) * 2004-02-26 2006-05-05 Sanofi Synthelabo ALKYLPIPERAZINE- AND ALKYLHOMOPIPERAZINE-CARBOXYLATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
US20070155747A1 (en) * 2005-12-29 2007-07-05 Kadmus Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
ITMI20061279A1 (en) * 2006-06-30 2008-01-01 Consiglio Nazionale Ricerche SELECTIVE NICOTINIC AGONISTS FOR THE ALFA7 RECEPTOR SUBTIPLE, PROCEDURE FOR THEIR PREPARATION AND RELATED PHARMACEUTICAL COMPOSITIONS
JO3598B1 (en) * 2006-10-10 2020-07-05 Infinity Discovery Inc Boronic acids and esters as inhibitors of fatty acid amide hydrolase
WO2009011904A1 (en) * 2007-07-19 2009-01-22 Renovis, Inc. Compounds useful as faah modulators and uses thereof
CA2710743A1 (en) * 2007-12-27 2009-07-09 Bial-Portela & Ca., S.A. 5-o-substituted 3-n-phenyl-1,3,4-oxadiazolones for medical use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1813606A1 (en) * 2004-11-18 2007-08-01 Takeda Pharmaceutical Company Limited Amide compound
WO2009094445A2 (en) * 2008-01-25 2009-07-30 E. I. Du Pont De Nemours And Company Fungicidal hetercyclic compounds

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
ALAN P. KOZIKOWSKI ET AL: "Methods for the stereoselective cis-cyanohydroxylation and -carboxyhydroxylation of olefins", THE JOURNAL OF ORGANIC CHEMISTRY, vol. 48, no. 3, 1 February 1983 (1983-02-01), pages 366 - 372, XP055060318, ISSN: 0022-3263, DOI: 10.1021/jo00151a017 *
BOYD E C ET AL: "Stereoselective cycloaddition of nitrile oxides to 4-vinyl-oxazolines and -oxazolidines", TETRAHEDRON LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 34, no. 19, 7 May 1993 (1993-05-07), pages 3169 - 3172, XP027190938, ISSN: 0040-4039, [retrieved on 19930507] *
CAETANO V F ET AL: "Preparation of beta-hydroxyesters from isoxazolines. A selective Ni<0>bpy-catalyzed electrochemical method", TETRAHEDRON LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 44, no. 45, 3 November 2003 (2003-11-03), pages 8217 - 8220, XP004463828, ISSN: 0040-4039, DOI: 10.1016/J.TETLET.2003.09.081 *
DALLANOCE ET AL: "Synthesis of enantiopure DELTA<2>-isoxazoline derivatives and evaluation of their affinity and efficacy profiles at human beta-adrenergic receptor subtypes", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, vol. 14, no. 13, 1 July 2006 (2006-07-01), pages 4393 - 4401, XP005445080, ISSN: 0968-0896, DOI: 10.1016/J.BMC.2006.02.038 *
LICHTMAN A H ET AL: "Reversible Inhibitors of Fatty Acid Amide Hydrolase That Promote Analgesia: Evidence for an Unprecedented Combination of Potency and Selectivity", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, AMERICAN SOCIETY FOR PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, US, vol. 311, no. 2, 1 November 2004 (2004-11-01), pages 441 - 448, XP008092330, ISSN: 0022-3565, DOI: 10.1124/JPET.104.069401 *
LUCA CECCHI ET AL: "1,4-Diazabicyclo[2.2.2]octane (DABCO) as an Efficient Reagent for the Synthesis of Isoxazole Derivatives from Primary Nitro Compounds and Dipolarophiles: The Role of the Base", EUROPEAN JOURNAL OF ORGANIC CHEMISTRY, vol. 2006, no. 21, 1 November 2006 (2006-11-01), pages 4852 - 4860, XP055060350, ISSN: 1434-193X, DOI: 10.1002/ejoc.200600475 *
MÉLINA GIRARDIN ET AL: "Synthesis of 3-Aminoisoxazoles via the Addition-Elimination of Amines on 3-Bromoisoxazolines", ORGANIC LETTERS, vol. 11, no. 5, 5 March 2009 (2009-03-05), pages 1159 - 1162, XP055060354, ISSN: 1523-7060, DOI: 10.1021/ol9000284 *
OLGA A. IVANOVA ET AL: "Application of a Thermal [beta]-Elimination Reaction to N -Alkoxy-3,3-dinitro­isoxazolidines: Synthesis of 3-Nitroisoxazolines", SYNTHESIS, vol. 2006, no. 04, 1 January 2006 (2006-01-01), pages 706 - 710, XP055060423, ISSN: 0039-7881, DOI: 10.1055/s-2006-926312 *
PAOLA CONTI ET AL: "Stereoselective Synthesis of 4-Amino-3-hydroxy-4,5,6,6a-tetrahydro-3a H -cyclopenta[ d ]isoxazole-4-carboxylic Acid, a Conformationally Constrained Analogue of Aspartic Acid", SYNTHESIS, vol. 2007, no. 14, 1 July 2007 (2007-07-01), pages 2145 - 2148, XP055060420, ISSN: 0039-7881, DOI: 10.1055/s-2007-983750 *
PAOLA CONTI ET AL: "synthesis of new [Delta]2-isoxazoline derivatives and their pharmacological characterization as [beta]-adrenergic receptor antagonists", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 6, no. 4, 1 April 1998 (1998-04-01), pages 401 - 408, XP055060381, ISSN: 0968-0896, DOI: 10.1016/S0968-0896(97)10051-7 *
ROVER S ET AL: "SYNTHESIS AND BIOCHEMICAL EVALUATION OF N-(4-PHENYLTHIAZOL-2-YL)BENZENESULFONAMIDES AS HIGH-AFFINITY INHIBITORS OF KYNURENINE 3-HYDROXYLASE", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 40, no. 26, 1 January 1997 (1997-01-01), pages 4378 - 4385, XP002920329, ISSN: 0022-2623, DOI: 10.1021/JM970467T *
See also references of WO2010135360A1 *
WADE P A ET AL: "DIASTEREOFACIAL SELECTIVITY STUDIES ON 3-ALKENYL-4,5-DIPHENYL-4,5-DIHYDROISOXAZOLES", JOURNAL OF ORGANIC CHEMISTRY, ACS, US, vol. 55, 1 January 1990 (1990-01-01), pages 3045 - 3051, XP002928748, ISSN: 0022-3263, DOI: 10.1021/JO00297A018 *

Also Published As

Publication number Publication date
MX2011012263A (en) 2012-01-30
RU2539595C2 (en) 2015-01-20
AR076687A1 (en) 2011-06-29
NZ619076A (en) 2015-07-31
CA2762527A1 (en) 2010-11-25
RU2011151635A (en) 2013-06-27
KR20120042766A (en) 2012-05-03
BRPI1011049A2 (en) 2019-09-24
WO2010135360A1 (en) 2010-11-25
CN102459202B (en) 2015-11-25
SG10201402443PA (en) 2014-10-30
TW201043620A (en) 2010-12-16
ZA201108657B (en) 2013-01-30
NZ596585A (en) 2014-01-31
CN102459202A (en) 2012-05-16
AU2010249674A1 (en) 2011-12-15
IL216420A0 (en) 2012-03-01
JP2012527467A (en) 2012-11-08
EP2432771A1 (en) 2012-03-28
SG176168A1 (en) 2011-12-29

Similar Documents

Publication Publication Date Title
IL216420A0 (en) Isoxazolines as inhibitors of fatty acid amide hydrolase
IL208536A0 (en) Inhibitors of fatty acid amide hydrolase
ZA201203371B (en) Azocyclic inhibitors of fatty acid amide hydrolase
ZA201700326B (en) Inhibitors of beta-secretase
IL218018A0 (en) Novel n-substituted-pyrrolidines as inhibitors of mdm2-p-53 interactions
IL215206A0 (en) Solid forms of an azocyclic amide
IL225769A0 (en) Piperidin-4-yl-azetidine diamides as monoacylglycerol lipase inhibitors
ZA201206424B (en) Inhibitors of semicarabazide-sensitive amine oxidase
ZA201006719B (en) Substituted dihydropyrazolones as inhibitors of hif-prolyl-4-hydroxylases
EP2637660A4 (en) Fatty acid synthase inhibitors
IL225815A0 (en) Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors
EP2493310A4 (en) Benzimidazoles as fatty acid synthase inhibitors
IL215645A0 (en) Inhibitors of cognitive decline
EP2503890A4 (en) Azabenzimidazoles as fatty acid synthase inhibitors
IL217833A0 (en) Inhibitors of cognitive decline
IL221281A0 (en) Fatty acid amide hydrolase inhibitors
IL213354A (en) Alpha-derivatives of cis-monounsaturated fatty acids for use as medicines
IL229020A0 (en) Fatty acid amide hydrolase inhibitors for treating pain
AU2012245196A8 (en) Fatty acid amide hydrolase inhibitors for treating pain
EP2542232A4 (en) Fatty acid inhibitors
EP2416660A4 (en) Inhibitors of fatty acid amide hydrolase
ZA201209042B (en) Modulators of fatty acid amide hydrolase
LU91725B1 (en) Novel uses of V-ATPASE inhibitors

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20111216

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1168352

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20130507

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 261/02 20060101AFI20130430BHEP

17Q First examination report despatched

Effective date: 20140507

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160907

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1168352

Country of ref document: HK